Search

San Diego Life Sciences Roundup: ResMed, Alexandria GradLabs & More

SAN DIEGO LIFE SCIENCES ROUNDUP: RESMED, ALEXANDRIA GRADLABS & MORE

Spring has sprung, and it's shaping up to be another busy season for San Diego's life sciences community. As we head into the weekend,...

Bio Roundup: Gottlieb Exits, Bristol Defends, Biogen Buys & More

BIO ROUNDUP: GOTTLIEB EXITS, BRISTOL DEFENDS, BIOGEN BUYS & MORE

In early 2017, Scott Gottlieb was considered the most moderate of the potential candidates to head the Food and Drug Administration,...

 
 
 
FDA Commissioner Scott Gottlieb Announces He Will Resign

FDA COMMISSIONER SCOTT GOTTLIEB ANNOUNCES HE WILL RESIGN

Gottlieb, who will resign in a month, stood out in the Trump administration for his efforts to regulate the tobacco and pharmaceutical...

HERON THERAPEUTICS TO PRESENT AT THE 39TH ANNUAL COWEN HEALTHCARE CONFERENCE

SAN DIEGO, March 4, 2019 /PRNewswire/ - Heron Therapeutics, Inc. , a commercial-stage biotechnology company focused on improving the...

 
 
 
Lilly to Launch “Authorized Generic” Insulin Priced at 50% Discount

LILLY TO LAUNCH “AUTHORIZED GENERIC” INSULIN PRICED AT 50% DISCOUNT

Eli Lilly is planning to offer a generic version of its blockbuster insulin product that will cost patients approximately half as much....

APELLIS RESUMES PHASE 3 AMD TRIALS AFTER ADDRESSING SAFETY ISSUE

Apellis Pharmaceuticals has resumed dosing in phase 3 trials of its treatment for an advanced form of age-related macular degeneration....

 
 
 

HALOZYME TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SAN DIEGO, March 4, 2019 /PRNewswire/ - Halozyme Therapeutics, Inc. , a biotechnology company developing novel oncology and drug-delivery...

PRECLINICAL ACCOUNT MANAGER - HEALTHCAREJOBS365 - NATIONAL CITY, CA

Maintain current business while identifying and developing new business opportunities in the biotechnology and pharmaceutical sectors...

 
 
 
After a Speedy IPO, Equillium Expands Antibody R&D to Renal Disease

AFTER A SPEEDY IPO, EQUILLIUM EXPANDS ANTIBODY R&D TO RENAL DISEASE

Equillium, a biotech that's looking to develop an antibody drug for immuno-inflammatory diseases, has added a form of renal disease...

 
 
 
Rani's “Robotic Pill” for Biologics Clears First Hurdle in Humans

RANI'S “ROBOTIC PILL” FOR BIOLOGICS CLEARS FIRST HURDLE IN HUMANS

Swallowing a pill is a convenience that's not available for all drugs. The cells and proteins in biological therapies can't survive...

Bristol-Myers' $74B Celgene Buyout Faces Opposition from Wellington

BRISTOL-MYERS' $74B CELGENE BUYOUT FACES OPPOSITION FROM WELLINGTON

Bristol-Myers Squibb's $74 billion agreement to acquire Celgene is opposed by the New York pharmaceutical company's largest institutional...

 
 
 
One chart from a big pharma CEO reveals how drug pricing in the US really works

ONE CHART FROM A BIG PHARMA CEO REVEALS HOW DRUG PRICING IN THE US REALLY WORKS

US drugs are expensive, and prices are rising. But executives at 7 top pharmaceutical companies testified at a Congressional hearing...

Pharmaceutical Company CEOs Face Grilling in Senate Over High Drug Prices

PHARMACEUTICAL COMPANY CEOS FACE GRILLING IN SENATE OVER HIGH DRUG PRICES

Senators called pharmaceutical industry leaders to account for the high costs of medicine during Senate testimony. The executives deflected...

 
 
 
Pharmaceutical industry execs say quick fix to drug prices could hurt future of medicine

PHARMACEUTICAL INDUSTRY EXECS SAY QUICK FIX TO DRUG PRICES COULD HURT FUTURE OF MEDICINE

Before U.S. senators, top industry officials are accounting for how they price their medicines.

 
 
 

IN VIVO RESEARCH ASSOCIATES

BTS Research is seeking Research Associates for the In Vivo department. This exciting opportunity takes place at a CRO in Sorrento...

NOVARTIS PAYS $150M TO LICENSE AKCEA-IONIS CARDIAC DISEASE DRUG

Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics...

 
 
 

SCIENTISTS EAVESDROP ON DNA SYNTHESIZER TO STEAL GENETIC BLUEPRINT

During the DNA synthesis process in a laboratory, recordings can be made of the subtle, telltale noises made by synthesis machines....

IPSEN STRIKES $1.3B CLEMENTIA BUYOUT TO BOOST RARE DISEASE UNIT

Ipsen has struck a $1.3 billion deal to buy Clementia Pharmaceuticals for its late-phase rare disease drug palovarotene. The transaction...